Healthcare Equity Valuation Framework
Value healthcare companies using disease economics, clinical pipelines, and regulatory catalysts
What You Can Do
You can construct institutional-grade healthcare valuation models that properly weight clinical and regulatory event risk. This skill teaches you to integrate disease-state economics (market sizing, competitive positioning), probability-adjusted NPV calculations for clinical programs, and financial runway analysis into cohesive price targets. You'll generate transparent bull/base/bear scenarios tied to specific clinical readout dates and regulatory milestones that institutional investors expect.
Features
analyze addressable market size, standard of care, competitive positioning, and pricing power for each indication
assign realistic success rates and timelines to each clinical program stage, then discount to present value
build event calendars with binary/catalyst-driven valuation bridges between current price and milestone-based price targets
calculate cash burn, dilution risk, and financing needs to assess whether the company reaches profitability or value-creating milestones
construct base/bull/bear cases with sensitivity analysis on key assumptions (discount rate, terminal growth, clinical success rates)
compare EV/sales, EV/R&D spend, and pipeline-adjusted multiples across comparable healthcare companies at similar stages
quantify how much value each clinical program, regulatory approval, or market expansion scenario contributes to your price target
Example Output
Example 1: Biotech Company Valuation
Current Price: $28/share | Market Cap: $420M
Pipeline NPV Calculation:
- Phase 2 oncology program: 40% success rate × $280M peak sales × 15% NPV margin = $16.8M NPV
- Phase 3 rare disease: 65% success rate × $120M peak sales × 22% NPV margin = $17.2M NPV
- Preclinical asset: 15% success rate × $500M peak sales × 8% NPV margin = $6M NPV
- Total pipeline NPV: $40M
Price Target Build:
- Pipeline NPV: $40M
- Cash on hand: $85M
- Accumulated deficit: -$120M (already reflected in equity value)
- Diluted shares outstanding: 16M
- Implied enterprise value: $725M
- Fair value per share: $43.75
- Current discount to fair value: 36% (margin of safety for clinical risk)
Example 2: Regulatory Catalyst Timeline
| Event | Date | Probability | Bear Case | Base Case | Bull Case |
|---|---|---|---|---|---|
| Phase 2 efficacy readout | Q2 2025 | 70% | $22 (-21%) | $35 (+25%) | $48 (+71%) |
| FDA breakthrough designation | Q4 2025 | 65% of Phase 2 success | — | $42 (+50%) | $58 (+107%) |
| Phase 3 top-line | Q1 2027 | 55% | $18 (-36%) | $65 (+132%) | $85 (+204%) |
Example 3: Financial Runway Assessment
Quarterly cash burn: $12M | Cash on hand: $85M | Runway: ~7 quarters (21 months) | Next financing trigger: Phase 3 initiation (Q3 2025) | Dilution risk if fully diluted: 18% from equity raise
What's Included
- SKILL.md instruction file: complete methodology for healthcare valuation framework
- Disease-state analysis template: market sizing, standard-of-care competitive matrix, and pricing power assessment
- Clinical pipeline probability calculator: stage-by-stage success rates, timeline assumptions, and peak sales build
- Regulatory milestone timeline & valuation bridge: event calendar with binary/catalyst-driven price targets
- Multi-scenario DCF model framework: base/bull/bear case structure with sensitivity tables
Who It's For
- Equity research analysts covering healthcare, pharma, and biotech sectors
- Investment bankers valuing healthcare companies for M&A and capital raises
- Healthcare investors and venture capitalists assessing pipeline-dependent valuations
- Corporate development professionals at large pharma evaluating acquisition targets
- Healthcare fund managers and hedge fund analysts building conviction theses
Best For
- Valuing early-stage biotech and pharmaceutical companies with pre-revenue or early-revenue programs
- Building price targets ahead of clinical trial readouts and regulatory decisions
- Comparing valuations across healthcare companies with different pipeline maturity and risk profiles
- Creating institutional-quality equity research reports with transparent event-risk scenarios
- Stress-testing healthcare portfolio holdings against clinical and regulatory event calendars
You might also like
You can analyze equity charts to identify continuation patterns (flags, pennants, triangles), reversal patterns (head-and-shoulders, double tops/bottoms), and momentum breakouts using rule-based frameworks. Claude applies consistent validation criteria to assess pattern strength, calculate precise risk/reward ratios based on pattern geometry, and identify early invalidation signals that trigger stop-loss placement—transforming subjective chart reading into systematic, probability-weighted trading decisions.
by steelmorgan
You can conduct deep-dive REIT financial analysis by translating GAAP accounting into real estate-specific valuation frameworks. The skill helps you calculate Funds From Operations, compare price-to-NAV ratios across property sectors, assess distribution sustainability, identify red flags in quarterly earnings, and evaluate comparable company multiples within residential, office, retail, industrial, or healthcare property segments. You'll produce institutional-grade investment recommendations backed by quantified risk metrics and confidence intervals.
by steelmorgan
You can transform fragmented ESG data from multiple vendors (MSCI, Sustainalytics, Bloomberg) into cohesive integration frameworks that clearly map ESG factors to investment thesis and financial outcomes. This skill helps you identify data conflicts, resolve vendor discrepancies, establish materiality-weighted scoring systems, and document audit trails that demonstrate defensible ESG integration decisions to institutional investors and regulators.
by steelmorgan
This skill accelerates your alternative asset evaluation by organizing complex fund assessments across hedge funds, private equity, real assets, and structured products into standardized, comparable frameworks. You can evaluate manager capability, operational infrastructure, fee alignment, and risk exposure while automatically flagging red flags—reducing cognitive load and maintaining institutional-grade rigor across disparate asset classes.
by steelmorgan
You can rigorously validate algorithmic trading strategies by decomposing backtest performance, identifying which components drive returns, and stress-testing robustness across market regimes. This skill exposes hidden validation gaps—like curve-fitting bias and survivorship errors—that cause live trading failures, helping you separate genuine alpha from statistical artifacts before deploying capital.
by steelmorgan
You can rapidly analyze corporate catalysts—mergers, bankruptcies, restructurings, regulatory decisions, and special situations—to uncover price dislocations and asymmetric payoff opportunities. This skill structures your catalyst research, quantifies probability-weighted outcomes, assesses execution risk and deal mechanics, and identifies mispriced event risk before consensus recognition. You'll synthesize multi-source event information and stress-test your investment thesis against alternative scenarios.
by steelmorgan
You'll construct sophisticated DCF models that treat each clinical asset as a branching probability tree, weighting revenue contributions by phase-specific success rates (Phase I: 30%, Phase II: 33%, Phase III: 25-30%, FDA approval: 80-90%). This approach replaces deterministic sales projections with realistic scenario ranges, enabling you to value pre-revenue or early-revenue biotechs by their pipeline potential, regulatory trajectory, and time-to-market dynamics. The skill guides you through setting risk-adjusted discount rates (10-15% above pharma majors) and conducting sensitivity analyses that institutional investors expect.
by fission
You can systematically validate derivative pricing models before deployment by comparing analytical solutions against numerical methods, detecting arbitrage opportunities and calibration issues, and performing sensitivity analysis across market conditions. Claude orchestrates multi-framework validation workflows that stress-test exotic options under extreme scenarios, optimize computational efficiency, and generate audit-ready documentation for model governance—catching model errors before they propagate to trading systems.
by steelmorgan